ArticleThe Journal of antibiotics2018
Asenjonamides A-C, antibacterial metabolites isolated from Streptomyces asenjonii strain KNN 42.f from an extreme-hyper arid Atacama Desert soil.
Article in The Journal of antibiotics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- The Blessed Clay from Boho, Northern Ireland: Can the Nature of Spiritual Healing Sites Guide us Towards New Sources of Drug Discovery?Journal of religion and health · 2026Article
- A novelFrontiers in microbiology · 2026Article
- Why Do FilamentousAnnual review of microbiology · 2025Review
- Strategies Used for the Discovery of New Microbial Metabolites with Antibiotic Activity.Molecules (Basel, Switzerland) · 2025Review
- Recombinant Expression and Characterization of a Novel Type I Baeyer-Villiger Monooxygenase from aInternational journal of molecular sciences · 2025Article
- Article
- Isolated from Populus euphratica rhizosphere soil, and mining their metabolites.Frontiers in microbiology · 2025Article
- Article
- Mining microbial and metabolic dark matter in extreme environments: a roadmap for harnessing the power of multi-omics data.Advanced biotechnology · 2024Review
- Metabolic Comparison and Molecular Networking of Antimicrobials inInternational journal of molecular sciences · 2024Article
- Going to extremes: progress in exploring new environments for novel antibiotics.npj antimicrobials and resistance · 2024Review
- War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.Frontiers in pharmacology · 2024Review
- Article
- Stalactites Core Prospect as Environmental "Microbial Ark": The Actinomycetota Diversity Paradigm, First Reported from a Greek Cave.Polish journal of microbiology · 2023Article
- Bioprospecting of desert actinobacteria with special emphases on griseoviridin, mitomycin C and a new bacterial metabolite producing Streptomyces sp. PU-KB10-4.BMC microbiology · 2023Article
- Promising bioactive compounds from the marine environment and their potential effects on various diseases.Journal, genetic engineering & biotechnology · 2022Review
- Whole-genome sequencing of two Streptomyces strains isolated from the sand dunes of Sahara.BMC genomics · 2021Article
- Mining Indonesian Microbial Biodiversity for Novel Natural Compounds by a Combined Genome Mining and Molecular Networking Approach.Marine drugs · 2021Article
- Actinobacteria From Desert: Diversity and Biotechnological Applications.Frontiers in microbiology · 2021Review
- Bioprospecting of Soil-Derived Actinobacteria Along the Alar-Hotan Desert Highway in the Taklamakan Desert.Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bio-guided fractionation of the culture broth extract of Streptomyces asenjonii strain KNN 42.f recovered from an extreme hyper-arid Atacama Desert soil in northern Chile led to the isolation of three new bioactive β-diketones; asenjonamides A-C (1-3) in addition to the known N-(2-(1H-indol-3-yl)-2-oxoethyl)acetamide (4), a series of bioactive acylated 4-aminoheptosyl-β-N-glycosides; spicamycins A-E (5-9), and seven known diketopiperazines (10-16). All isolated compounds were characterized by HRESIMS and NMR analyses and tested for their antibacterial effect against a panel of bacteria.
Indexed as
Identifiers
29362461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.